How does ETNB's PB Ratio compare to its peers?

ETNB is good value based on its Price-To-Book Ratio (2.7x) compared to the peer average (50.4x).

How does ETNB's PB Ratio compare vs other companies in the US Biotechs Industry?

ETNB is expensive based on its Price-To-Book Ratio (2.7x) compared to the US Biotechs industry average (1.8x).

What is ETNB's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate ETNB's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of ETNB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate ETNB's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

89bio (Nasdaq:ETNB) - Stock Price, News & Analysis

ETNB Stock Overview

A clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. More details

ETNB fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Risk Analysis

Makes less than USD$1m in revenue ($0)

Shareholders have been substantially diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

89bio, Inc. Competitors

Immatics

NasdaqCM:IMTX

US$904.7m

Applied Therapeutics

NasdaqGM:APLT

US$1.1b

Cogent Biosciences

NasdaqGS:COGT

US$991.9m

Gracell Biotechnologies

NasdaqGS:GRCL

US$990.8m

Price History & Performance

Summary of all time highs, changes and price drops for 89bio
Historical stock prices
Current Share Price	US$8.76
52 Week High	US$16.63
52 Week Low	US$7.00
Beta	0.98
11 Month Change	12.16%
3 Month Change	-1.07%
1 Year Change	10.61%
33 Year Change	-35.35%
5 Year Change	-71.99%
Change since IPO	-57.88%

Recent updates

89bio: Surviving A Competitive Space - For Now

Oct 29

Health Check: How Prudently Does 89bio (NASDAQ:ETNB) Use Debt?

Sep 26

89bio: Bullish In Light Of Further MOA Being Established By Peer

Aug 07

89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy

May 23

89bio Still Has A Chance As NASH Race Heats Up

Oct 06

89bio completes enrollment in phase 2 trial for NASH treatment

Aug 18

89Bio rallies on Deep Track Capital disclosing 10% stake

Jul 07

89bio: Undervalued Contender In Race For First NASH Drug Approval

Jul 20

We're Hopeful That 89bio (NASDAQ:ETNB) Will Use Its Cash Wisely

May 07

89bio: NASH Drug Developer With Differentiated Profile

Jan 29

Shareholder Returns

	ETNB	US Biotechs	US Market
7D	10.5%	2.4%	2.2%
1Y	10.6%	16.2%	31.7%

Return vs Industry: ETNB underperformed the US Biotechs industry which returned 15.2% over the past year.

Return vs Market: ETNB underperformed the US Market which returned 31.1% over the past year.

Price Volatility

Is ETNB's price volatile compared to industry and market?
ETNB volatility
ETNB Average Weekly Movement	9.2%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stable Share Price: ETNB has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: ETNB's weekly volatility (9%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2018	70	Rohan Palekar	www.89bio.com

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

89bio, Inc. Fundamentals Summary

How do 89bio's earnings and revenue compare to its market cap?
ETNB fundamental statistics
Market cap	US$985.34m
Earnings (TTM)	-US$288.96m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-3.6x

P/E Ratio

Is ETNB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ETNB income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$288.96m
Earnings	-US$288.96m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-2.46
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	9.4%

How did ETNB perform over the long term?

See historical performance and comparison

ETNB Stock Overview

Risk Analysis

89bio, Inc. Competitors

NasdaqCM:IMTX

US$904.7m

NasdaqGM:APLT

US$1.1b

NasdaqGS:COGT

US$991.9m

NasdaqGS:GRCL

US$990.8m

Price History & Performance

Recent News & Updates

89bio, Inc. has completed a Follow-on Equity Offering in the amount of $124.996747 million.

89bio, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

89bio: Surviving A Competitive Space - For Now

Health Check: How Prudently Does 89bio (NASDAQ:ETNB) Use Debt?

89bio, Inc. Appoints Teresa Perney as Chief Regulatory and Quality Officer

89bio: Bullish In Light Of Further MOA Being Established By Peer

Recent updates

89bio, Inc. has completed a Follow-on Equity Offering in the amount of $124.996747 million.

89bio, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

89bio: Surviving A Competitive Space - For Now

Health Check: How Prudently Does 89bio (NASDAQ:ETNB) Use Debt?

89bio, Inc. Appoints Teresa Perney as Chief Regulatory and Quality Officer

89bio: Bullish In Light Of Further MOA Being Established By Peer

89bio, Inc.(NasdaqGM:ETNB) dropped from Russell 2500 Growth Index

89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress

89Bio Initiates Phase 3 Enlighten-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (Mash) Patients with Compensated Cirrhosis

89bio, Inc., Annual General Meeting, May 29, 2024

89bio, Inc. Appoints Martin Babler to Its Board of Directors

89bio, Inc. Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis

89Bio, Inc. Announces Initiation of Its Phase 3 Enlighten Program Evaluating the Efficacy and Safety of Pegozafermin in Patients with Metabolic Dysfunction-Associated Steatohepatitis (Mash), Formerly Known as Nonalcoholic Steatohepatitis

89bio, Inc. announced delayed annual 10-K filing

CEO & Director notifies of intention to sell stock

89bio, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

89bio, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

89bio, Inc. Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)

89bio, Inc. Announces New Positive Long-Term Data from the ENLIVEN Phase 2B Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis

89bio, Inc. Announces New Positive Long-Term Data from the ENLIVEN Phase 2B Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis

89Bio Announces Additional Data from the Enliven Phase 2B Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis

Price target decreased by 9.4% to US$33.44

New minor risk - Share price stability

Price target increased by 7.8% to US$37.44

89bio, Inc. Announces Data from the Phase 2B Enliven Trial Evaluating Treatment with Pegozafermin in Patients with Nonalcoholic Steatohepatitis

89bio, Inc. Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia

Insider notifies of intention to sell stock

Consensus EPS estimates upgraded to US$2.01 loss

Chief Financial Officer notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Price target increased by 34% to US$33.75

Independent Director exercised options and sold US$92k worth of stock

Chief Financial Officer notifies of intention to sell stock

Price target increased to US$24.63

89bio, Inc. Announces Publication of Results of Phase 1B/2A Study of Pegozafermin for the Treatment of NASH in the Lancet Gastroenterology & Hepatology

Consensus forecasts updated

89bio Presents Additional Exploratory Analyses from the Phase 1b/2a NASH Study of Pegozafermin at AASLD The Liver Meeting(R) 2022

89bio Still Has A Chance As NASH Race Heats Up

Consensus forecasts updated

CEO & Director exercised options to buy US$478k worth of stock.

89bio, Inc. Presents Positive Results from Entrigue Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia At European Society of Cardiology Congress 2022

89Bio, Inc. Completes Enrollment in Enliven, the Phase 2B Trial of Pegozafermin for the Treatment of NASH

89bio completes enrollment in phase 2 trial for NASH treatment

89Bio rallies on Deep Track Capital disclosing 10% stake

89bio, Inc. has completed a Follow-on Equity Offering in the amount of $94.492054 million.

89bio, Inc. has completed a Follow-on Equity Offering in the amount of $94.492054 million.

89bio, Inc. Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)

89bio, Inc.(NasdaqGM:ETNB) dropped from Russell 2500 Index

Price target decreased to US$45.67

89bio, Inc., Annual General Meeting, Jun 01, 2022

Price target decreased to US$45.67

89bio, Inc. Appoints Edward Morrow Atkinson to the Board

CEO & Director recently bought US$53k worth of stock

89Bio, Inc. Announces Positive Topline Results from an Open-Label Expansion Cohort of 20 Patients in the Phase 1b/2a Trial of Pegozafermin (BIO89-100) for the Treatment of NASH

COO & Chief Business Officer notifies of intention to sell stock

COO & Chief Business Officer exercised options and sold US$102k worth of stock

COO & Chief Business Officer exercised options and sold US$109k worth of stock

COO & Chief Business Officer notifies of intention to sell stock

COO & Chief Business Officer exercised options and sold US$114k worth of stock